Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct OfferingBusiness Wire • about 2 months agoSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the...